Inpatient mortality and postpartum readmission rates in sickle cell disease pregnancies: a multistate analysis, 2007–2014 Academic Article Article uri icon


MeSH Major

  • Anti-Inflammatory Agents, Non-Steroidal
  • Ibuprofen


  • © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Objective: We compared post-partum outcomes between sickle cell disease (SCD) and non-sickle cell populations. Methods: We conducted a retrospective analysis of discharge data for 6,911,916 inpatient deliveries in the states of California, Florida, New York, Maryland, and Kentucky from 2007 to 2014 using data from the State Inpatient Databases, Healthcare Cost and Utilization Project. We compared unadjusted rates and adjusted odds of 30- and 90-d readmission rates, in-hospital mortality, length of stay (LOS), and total hospital charges in SCD, sickle cell trait, and non-sickle cell patients. Results: Compared to non-sickle cell patients, SCD patients were more than two times as likely to die in-hospital (aOR: 2.16, 95% CI: 1.15–4.04, p <.05), 27% as likely to be readmitted up to 30 d postdelivery (aOR: 1.27, 95% CI: 1.13–1.43, p <.001), and 92% as likely to be readmitted up to 90 d postdelivery (aOR 1.92, 95% CI: 1.75–2.11, p <.001). The SCD group also had a longer median LOS, greater total hospital charges, were more likely to experience a postpartum complication, and receive a blood transfusion than the non-SCD group. Conclusions: SCD in pregnancy is associated with increased inpatient mortality, readmissions, postpartum complications, LOS, and hospital charges.

publication date

  • January 2019



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1080/14767058.2019.1671333

PubMed ID

  • 31588827

Additional Document Info